Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.380 +0.380 (+38.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,130,976
Open 1.000
Bid (Size) 2.470 (63)
Ask (Size) 2.500 (23)
Prev. Close 1.000
Today's Range 0.9950 - 3.610
52wk Range 0.9423 - 180.19
Shares Outstanding 11,523,716
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment nearing completion. 
Via Benzinga

Performance

YTD
-69.8%
-69.8%
1 Month
-55.3%
-55.3%
3 Month
-68.0%
-68.0%
6 Month
-77.8%
-77.8%
1 Year
-99.1%
-99.1%

More News

Read More
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Via ACCESS Newswire
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Via ACCESS Newswire
Aptevo to Participate in March Conferences
Via ACCESS Newswire
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Via ACCESS Newswire
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Via ACCESSWIRE
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Via ACCESSWIRE
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Via ACCESSWIRE
What's Going On With Aptevo Therapeutics Shares Friday?
Via Benzinga
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
Via ACCESSWIRE
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Via ACCESSWIRE
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Via ACCESSWIRE
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Via ACCESSWIRE
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
Via ACCESSWIRE
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Aptevo Therapeutics Inc. - Common Stock publicly traded?
Yes, Aptevo Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Aptevo Therapeutics Inc. - Common Stock trade on?
Aptevo Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aptevo Therapeutics Inc. - Common Stock?
The ticker symbol for Aptevo Therapeutics Inc. - Common Stock is APVO on the Nasdaq Stock Market
What is the current price of Aptevo Therapeutics Inc. - Common Stock?
The current price of Aptevo Therapeutics Inc. - Common Stock is 1.380
When was Aptevo Therapeutics Inc. - Common Stock last traded?
The last trade of Aptevo Therapeutics Inc. - Common Stock was at 04/02/25 04:00 PM ET
What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 15.90M
How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
Aptevo Therapeutics Inc. - Common Stock has 16M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.